Investigations

GRABAR LAW OFFICE INVESTIGATES POTENTIAL SHAREHOLDER ACTION ON BEHALF OF CURRENT SHAREHOLDERS OF CHEMOCENTRYX, INC. (NASDAQ: CCXI)

Current ChemoCentryx, Inc. shareholders who have held shares of the Company’s stock since at least November 26, 2019, can seek corporate reforms, the return of funds back to company coffers and potentially a court approved incentive award if appropriate. 

The underlying class action complaint alleges that the defendants misrepresented and/or failed to disclose to investors that: (1) the study design of the Phase III ADVOCATE drug trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of AAV; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s NDA for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, the defendants’ public statements were materially false and misleading at all relevant times.

If you would like to learn more about this matter at no cost to you, please fill out the form provided or contact us at jgrabar@grabarlaw.com or call 267-507-6085.

Click here to review the ChemoCentryx, Inc. Derivative Retainer Letter.

Contact Us

Please enter your name.
Please enter a valid phone number.
Please enter a message.

Standard Derivative Form Retainer

Standard Form Derivative Retainer Letter - No Cost
  • Join This Action

  • Alternatively, you may upload your transactions using the upload button below or email them to jgrabar@grabarlaw.com. *

  • Drop files here or
    Max. file size: 100 MB.
    • Signed pursuant to California Civil Code Section 1633.1, et seq. and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.
    • Date of signing: *

    • MM slash DD slash YYYY
    • This field is for validation purposes and should be left unchanged.